Visakorpi T - Search Results

1

Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data.

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT, Visakorpi T, Nykter M, Maitland NJ. Rane JK, et al. Among authors: visakorpi t. Br J Cancer. 2015 Aug 11;113(4):611-5. doi: 10.1038/bjc.2015.262. Epub 2015 Jul 23. Br J Cancer. 2015. PMID: 26203762 Free PMC article.

2

Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.

Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T. Hyytinen ER, et al. Among authors: visakorpi t. Br J Cancer. 1997;75(2):190-5. doi: 10.1038/bjc.1997.32. Br J Cancer. 1997. PMID: 9010025 Free PMC article.

3

Human pHyde is not a classical tumor suppressor gene in prostate cancer.

Porkka KP, Nupponen NN, Tammela TL, Vessella RL, Visakorpi T. Porkka KP, et al. Among authors: visakorpi t. Int J Cancer. 2003 Sep 20;106(5):729-35. doi: 10.1002/ijc.11278. Int J Cancer. 2003. PMID: 12866033

4

Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.

Savinainen KJ, Linja MJ, Saramäki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T. Savinainen KJ, et al. Among authors: visakorpi t. Br J Cancer. 2004 Mar 8;90(5):1041-6. doi: 10.1038/sj.bjc.6601648. Br J Cancer. 2004. PMID: 14997205 Free PMC article.

5

Genetic aberrations in prostate cancer by microarray analysis.

Saramäki OR, Porkka KP, Vessella RL, Visakorpi T. Saramäki OR, et al. Among authors: visakorpi t. Int J Cancer. 2006 Sep 15;119(6):1322-9. doi: 10.1002/ijc.21976. Int J Cancer. 2006. PMID: 16642477

6

MicroRNA expression profiling in prostate cancer.

Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. Porkka KP, et al. Among authors: visakorpi t. Cancer Res. 2007 Jul 1;67(13):6130-5. doi: 10.1158/0008-5472.CAN-07-0533. Cancer Res. 2007. PMID: 17616669

7

Clusterin is epigenetically regulated in prostate cancer.

Rauhala HE, Porkka KP, Saramäki OR, Tammela TL, Visakorpi T. Rauhala HE, et al. Among authors: visakorpi t. Int J Cancer. 2008 Oct 1;123(7):1601-9. doi: 10.1002/ijc.23658. Int J Cancer. 2008. PMID: 18649357

8

TCEB1 promotes invasion of prostate cancer cells.

Jalava SE, Porkka KP, Rauhala HE, Isotalo J, Tammela TL, Visakorpi T. Jalava SE, et al. Among authors: visakorpi t. Int J Cancer. 2009 Jan 1;124(1):95-102. doi: 10.1002/ijc.23916. Int J Cancer. 2009. PMID: 18844214

9

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T. Waltering KK, et al. Among authors: visakorpi t. Cancer Res. 2009 Oct 15;69(20):8141-9. doi: 10.1158/0008-5472.CAN-09-0919. Epub 2009 Oct 6. Cancer Res. 2009. PMID: 19808968

10

miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.

Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H, Visakorpi T. Rauhala HE, et al. Among authors: visakorpi t. Int J Cancer. 2010 Sep 1;127(6):1363-72. doi: 10.1002/ijc.25162. Int J Cancer. 2010. PMID: 20073067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters